Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,848 total articles
Victoria's Secret has stopped trying to be everything to everyone and is once again selling aspirational lingerie and intimate apparel at healthier margins. The stock has room to re-rate as comps stabilize, promotional pressure eases and management monetizes new distribution channels. Enter a tactical long with a clear stop and a medium-term target…
Zeta Global (ZETA) is an AI-driven marketing cloud gaining traction with enterprise customers, showing ~50% YoY growth and 19 consecutive beat-and-raise quarters. The stock trades at roughly $7.0B market cap and is starting to show bullish technical momentum. This trade idea frames a long entry at $26.12, a protective stop at $20.00, and an ambitio…
Mitsui & Co. (MITSY) has been marked down from its 52-week high despite steady fundamentals: a $85B market cap, a 16.1x P/E, 1.6x PB, and a 2.14% yield. With institutional interest from Berkshire and positive energy/CCUS industry developments, the stock looks set for a mid-term bounce. This trade idea lays out a clear entry, stop, and target for a …
Celestica reported blowout growth last quarter and raised full-year guidance, but the stock has pulled back. Fundamentals point to continued upside from hyperscaler AI capex and custom server assembly work. This trade idea sets a clear entry at $315.00, stop at $285.00 and a $420.00 target over a 180 trading-day horizon with a medium risk profile.
Nano Labs (NA) is a small fabless designer of high-throughput and vision computing chips trading at $1.85 and a market cap of roughly $44.8M. The company sits squarely in two of the market's hottest secular themes - AI acceleration and edge vision - and recent corporate moves signal an intent to expand into North America. With attractive accounting…
ANI Pharmaceuticals (ANIP) looks like a buy for patient traders. The market is focused on recent execution - which has been solid - but may be underpricing the commercial and rare-disease optionality from ILUVIEN and continued rare-disease tailwinds. With a market cap near $1.82B, FCF of $179M and management guiding to north of $1B in revenue for 2…
MNTN looks set to trade higher as operating cash flow catches up with earnings and the company's net-cash balance sheet separates enterprise value from headline market cap. Premium multiples still price growth, but a clear path to stronger free cash generation and several near-term catalysts create a pragmatic trade: enter at $10.30, target $14.00,…
MPLX reported a quarter that felt soft at face value, but underlying cash generation, an intact distribution and modest deleveraging mean the business risk just dropped. The stock trades at roughly $60, yields ~7.1%, and carries tangible upside if volumes and project execution remain steady. This trade idea lays out an entry at $59.50, a stop at $5…
Innoviva is facing genuine royalty roll-off concerns, but the stock's current valuation - roughly $1.52B market cap, P/E ~3, EV/EBITDA ~5.8 and an implied FCF yield near 12% - already factors in a dramatic earnings collapse. That makes a tactical long with defined risk-management attractive. This trade plan lays out entry, stop and layered targets …
NRG's recent LS Power acquisition (13 GW added) and raised FY26 guidance materially enlarge its generation footprint and optionality into data-center power. The numbers show upgraded EBITDA and FCF guidance, but the balance sheet and prior quarterly noise argue for an active, risk-managed long. This trade idea targets $150 with a $110 stop over a 1…
Radian's recent quarter disappointed as newly acquired P&C and specialty lines pressured results, but the balance sheet remains healthy, the stock trades below 10x earnings, and the company's strategic pivot (including the $1.7B Inigo deal) points to upside. This is a tactical long for the mid term (45 trading days) with defined entry, stop and tar…
Consolidated Edison (ED) is a classic regulated-utility buy: predictable cash flow, a rising dividend (52 consecutive years), and a reasonable valuation (P/E ~18, P/B ~1.4). I expect low-single-digit EPS growth, a 3%+ starting yield, and the potential for multiple expansion and capital appreciation that combine to deliver double-digit annualized to…
Meta's multi-year AI investment is expensive, but the company now has a credible pathway to monetize a ~3.6 billion user base with AI-driven ads and experiences. Recent weakness has left the stock attractively priced relative to the upside from AI-enabled product improvements. This trade idea lays out an actionable long with entry, stop, and target…
Sanofi is trading at $43.26 with a $103.1B market capitalization, a 4.11% yield, and recent top-line momentum led by Dupixent. Q2 showed 17.8% constant-currency sales growth and management upgraded 2026 guidance. The stock’s valuation, current technicals and modest short interest create an asymmetric long opportunity for investors willing to hold t…
Alphabet combines a dominant ad/search franchise with fast-growing cloud AI demand and a pristine balance sheet. At ~$364.59 the stock trades at a mid-teens P/E with meaningful free cash flow and margin optionality. This trade idea lays out a concrete entry, stop and target for a long-term (180 trading days) position and the catalysts and risks to …
First Solar (FSLR) combines industry-leading module technology with strong free cash flow, no meaningful debt, and a mid-teens P/E. The stock pulled back into the $225-$240 area after recent volatility. For investors willing to own a high-conviction solar name through policy and project execution noise, this offers an attractive risk-reward: enter …
Rocket Lab has shifted decisively from a pure-play commercial launcher to a vertically integrated space and defense company. Recent contract wins totaling hundreds of millions, a growing backlog and a strategic Iridium acquisition create a path to 2027 profitability. The valuation is rich, but the balance sheet, contract cadence and a clear go-to-m…
Palantir’s Q2 blowout and follow-through rally have combined fundamental acceleration and technical confirmation. Despite steep multiples, revenue growth, FCF generation and improving breadth make a mid-term long trade attractive. Entry at $160, stop at $140, target $200 with a 45 trading-day horizon.
Amkor (AMKR) has been a direct beneficiary of the AI-driven bump in packaging and test demand but still trades at reasonable multiples. The company's $1.69B Q1 revenue beat, optimistic Q2 guidance, and a 10-year capacity partnership with TSMC argue for upside. I present a swing trade plan to capture re-rating into $75 while keeping a disciplined st…
Zeta Global's revenue acceleration and sizable free cash flow have finally begun to show up at the bottom line. With a visible partnership pipeline and recurring revenue tailwinds, the stock looks tradeable on a mid-term horizon. This plan defines an entry, stop and target while laying out catalysts and the key risks that would invalidate the setup…
The market appears fixated on short-term launch and regulatory headlines while underweighting recurring revenue potential and margin leverage in Starlink plus strategic optionality from Starship commercialization. This trade idea buys that disconnect: enter at $250.00, target $350.00, stop $200.00 over a 180-trading-day horizon.
Palantir's accelerating AIP adoption and clearer path to higher-margin revenue have convinced me to raise my target to $38. This is a tactical long for patient, risk-aware traders: entry at $25.00, stop at $21.00, target at $38.00 over a long-term (180 trading days) horizon.
ASML has been punished recently on headlines about a Chinese DUV vendor and an AI sector pullback. Fundamentals and capacity math still favor ASML's EUV franchise. This is a tactical long: enter on the dip, size for a mid-term (45 trading days) swing, protect with a tight stop and take profits into a known resistance band near $1,900.
ON Semiconductor's $7 billion Synaptics acquisition and management's synergy roadmap materially change the company's growth profile. With free cash flow of $1.5B, an EPS of $2.65 and a reasonable balance sheet, I am raising my price target to reflect a re-rated multiple for physical-AI exposure. This is an actionable idea: buy near $76.50, target $…
BrainsWay (BWAY) is a niche leader in Deep Transcranial Magnetic Stimulation (Deep TMS) with recent regulatory wins and research grants that support adoption. With a ~$608M market cap and a compact workforce, the company can grow clinic penetration without heavy capex. This trade idea takes a mid-term bullish stance into Q2 results and potential co…
